Showing Results for: “Glycemic Index and Diabetes”

The American Diabetes Association (ADA) announces this year’s National Scientific and Health Care Achievement Award recipients The American Diabetes Association ® (ADA) is proud to announce the recipients of the 2020 National Scientific and Health Care Achievement Awards. The awards recognize academics, health care providers and educators who have contributed to tangible advances in the field of diabetes care and research. Each recipient has shown outstanding commitment to achieving the vision of the ADA: life free of diabetes and all its burdens. “I am thrilled to recognize the eight talented

The American Diabetes Association (ADA) welcomes the 2020 Principal Officers and Board of Directors. The 18-member board is comprised of forward-thinking, innovative medical, scientific, education and executive professionals, who will strategically lead and focus efforts to ensure the ADA continues to be synonymous with excellence. "We are thrilled to welcome the newest members of ADA’s National Board of Directors,” said Tracey D. Brown, Chief Executive Officer of the ADA. “With the help of these talented and dedicated experts, we will continue the important work that leads us closer and

This World Diabetes Day, Know Diabetes by Heart™ national spokespeople spotlight the link between type 2 diabetes and cardiovascular disease Today, on World Diabetes Day, the American Heart Association and the American Diabetes Association, two of the world’s leading health organizations in the areas of cardiovascular diseases and diabetes, announce new patient spokespeople for Know Diabetes by Heart ™ , a joint initiative to inspire more than 30 million Americans living with diabetes to lower their risk for cardiovascular death, heart attacks, heart failure and stroke. Five ambassadors and

The diabetes medications glimepiride and linagliptin had similar impacts on cardiovascular morbidity and mortality for a median period of 6.3 years, when added to standard care for people with relatively early type 2 diabetes (T2D), many of whom had an elevated risk of cardiovascular disease (CVD) or existing CVD at the beginning of the study, according to research presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study was featured today at “The CAROLINA Trial—First Results of the Cardiovascular

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now report on the extensive development of severe renal, cardiac, eye, nerve, and pregnancy complications in early adulthood in patients with youth-onset type 2 diabetes. Results from this follow up study, TODAY2, presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®, show an accelerating rate of serious complications within the last five years and point to the increased

Peter Rossing, MD, DMSc, has been selected to receive the American Diabetes Association’s® (ADA’s) 2019 Edwin Bierman Award. This award recognizes a leading scientist who has made outstanding contributions in the field of diabetes-related macrovascular complications and related risk factors. Dr. Rossing will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7–11, 2019, at the Moscone Convention Center in San Francisco. He will deliver his Edwin Bierman Award Lecture, titled “ Linking Kidney and Cardiovascular Complications—Impact on Prognosis and Treatment ,” on

Assiamira Ferrara, MD, PhD, has been selected to receive the American Diabetes Association’s® (ADA’s) 2019 Norbert Freinkel Award, given in memory of Norbert Freinkel, a dedicated investigator and industry thought leader. The Norbert Freinkel Award honors a researcher who has made outstanding contributions—including scientific publications and presentations—to the understanding and treatment of diabetes in pregnancy. Dr. Ferrara will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7–11, 2019, at the Moscone Convention Center in San Francisco. She will deliver the

James Wrobel, DPM, MS, has been selected to receive the American Diabetes Association’s® (ADA’s) 2019 Roger Pecoraro Award. This award recognizes a researcher who has made significant scientific contributions and demonstrates an untiring commitment to improving the understanding of the detection, treatment, and prevention of diabetic foot complications. Dr. Wrobel will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. He will deliver the Roger Pecoraro Award Lecture, “ Artificial Intelligence for

The American Diabetes Association (ADA) is honored to welcome the 2019 Principal Officers and Board of Directors. The 18-member board is comprised of forward-thinking medical, scientific, education and executive professionals, who will strategically lead and focus efforts to ensure the ADA continues to be synonymous with excellence. "The newest members of ADA’s National Board of Directors are respected and trusted leaders within their professions, and we are thankful they are willing to share their time and energy to help us bend the curve on the diabetes epidemic,” said Tracey D. Brown, Chief

The U.S. Food and Drug Administration (FDA) convened the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC) on May 27, 2021, to review Teplizumab, which has shown the ability to delay the onset of Type 1 diabetes symptoms by two years. The American Diabetes Association ® (ADA) applauds the FDA Advisory Committee’s approval of Teplizumab for those at risk for developing type 1 diabetes (T1D). Click here to view the official comments submitted by the ADA. In response, Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA shared the following: “This is undoubtedly